scispace - formally typeset
S

Sekhar Surapaneni

Researcher at Celgene

Publications -  25
Citations -  470

Sekhar Surapaneni is an academic researcher from Celgene. The author has contributed to research in topics: Excretion & Pharmacokinetics. The author has an hindex of 9, co-authored 25 publications receiving 415 citations.

Papers
More filters
Journal ArticleDOI

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

TL;DR: Following oral administration, pomalidomide was well absorbed, with parent compound being the predominant circulating component, and metabolites were eliminated primarily in urine.
Journal ArticleDOI

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

TL;DR: Following oral administration, lenalidomide is highly absorbed and bioavailable, metabolized minimally, and eliminated predominantly via urinary excretion in the unchanged form in humans.
Journal ArticleDOI

Disposition, metabolism and mass balance of [14C]apremilast following oral administration

TL;DR: Apremilast is a novel, orally available small molecule that specifically inhibits PDE4 and thus modulates multiple pro- and anti-inflammatory mediators, and is currently under clinical development for the treatment of psoriasis and psoriatic arthritis.
Journal ArticleDOI

Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas

TL;DR: The immune stimulatory effects of lenalidomide, administrated to mice in doses, which provided comparable pharmacokinetics to human patients, on the potency of a novel fusion DNA lymphoma vaccine were investigated and results confirm and extend results from other models describing the effect of len Khalidomide on enhancing T-cell immunity.
Journal ArticleDOI

Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary.

TL;DR: It is submitted that radiolabeled animal ADME studies still provide a definitive and irreplaceable component of the understanding of the in vivo actions and behaviors of drugs and should continue to be performed prior to the exposure of large numbers of human subjects to investigative drugs.